Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

THG rejects 'unfunded' offer for Myprotein

(Sharecast News) - Online retailer THG on Wednesday rejected a "largely unfunded" bid for its Myprotein business worth up to £600m from AIM-listed acquisition vehicle Selkirk - led by its former chairman. The "highly conditional" cash and share offer valued Myprotein at £400m - £600m on a cash-free, debt-free basis, the company said in a statement. Selkirk was set up by two early backers of THG, including its previous chairman Iain McDonald and shares in the firm were up almost 6% in London trade.

"The board considered that the proposal fundamentally undervalued Myprotein and its prospects, and in addition carried significant execution complexity and risks, in particular the ability of Selkirk to raise sufficient funding," it added.

Selkirk is a shell investment vehicle that floated last November, having been founded with funds from Kelso - an activist investor and major shareholder in THG.

McDonald stood down from THG after a shareholder rebellion against his re-election at the company's annual general meeting in 2023. The board backed him, but he stepped down in March 2024.

THG has been undergoing a restructure after pressure from activist investors over the decline in the price of its shares, which listed at 500p apiece in 2020.

THG, which is scheduled to post first quarter figures next Wednesday, said it had reduced debt and secured long-term banking facilities since spinning off its Ingenuity technology platform and distribution business at the start of the year.

Reporting by Frank Prenesti for Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.